SCHEMBL25296388

SCHEMBL25296388

Cc1n[nH]c2c1C(=O)C(=O)c1ccccc1-2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 5/20 0.49
CCNE2 O96020 4/20 0.49
CCNE1 P24864 4/20 0.49
CDK4 P11802 3/20 0.49
CCND1 P24385 3/20 0.49
POLB P06746 4/20 0.42
RAB9A P51151 3/20 0.42
APAF1 O14727 2/20 0.42
PAX8 Q06710 1/20 0.42
CHEK1 O14757 2/20 0.42
AKT2 P31751 1/20 0.42
KDM4E B2RXH2 3/20 0.41
LMNA P02545 3/20 0.41
MAPT P10636 3/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
BLM P54132 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 2/20 0.41
MAPK1 P28482 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29404936 1.00 CDK2 (0.49) CDK2CCNE2CCNE1CDK4CCND1
SCHEMBL13010028 0.95 CCNE2 (0.54) CDK2CCNE2CCNE1CDK4CCND1
SCHEMBL9672281 0.77 MEN1 (0.50) PAX8MEN1KMT2ABLMTDP2
SCHEMBL9673690 0.75 CCNE2 (0.58) CDK2CCNE2CCNE1CDK4CCND1
SCHEMBL6749017 0.75 CDK4 (0.52) CDK2CCNE2CCNE1CDK4CCND1
SCHEMBL4025522 0.70 CCNE2 (0.71) CDK2CCNE2CCNE1CDK4CCND1
SCHEMBL7090159 0.70 CDK4 (0.71) CDK2CCNE2CCNE1CDK4CCND1
SCHEMBL14519404 0.67 MAPK14 (0.47) CDK2CCNE2CCNE1CDK4CCND1
SCHEMBL7148608 0.67 CDK4 (0.66) CDK2CCNE2CCNE1CDK4CCND1
SCHEMBL21970645 0.66 MAOB (0.65) POLBRAB9AAPAF1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570613-B2 Imidazoquinoline or benzoindazolone compound and intermediate for preparing same LMITO THERAPEUTICS INC. (KR) 2026-03-10 US claimed
US-20240034719-A1 IMIDAZOQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME LMITO THERAPEUTICS INC. (KR) 2024-02-01 US claimed
EP-4212530-A1 IMIDAZOLQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME Lmito Therapeutics Inc. (KR) 2023-07-19 EP claimed
US-12570613-B2 Imidazoquinoline or benzoindazolone compound and intermediate for preparing same LMITO THERAPEUTICS INC. (KR) 2026-03-10 US disclosed
US-20240034719-A1 IMIDAZOQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME LMITO THERAPEUTICS INC. (KR) 2024-02-01 US disclosed
EP-4212530-A1 IMIDAZOLQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME Lmito Therapeutics Inc. (KR) 2023-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240034719-A1 IMIDAZOQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME NQO1, NFE2L2, KEAP1 CDK2 366/4885CCNE2 717/4885CCNE1 1261/4885
US-12570613-B2 Imidazoquinoline or benzoindazolone compound and intermediate for preparing same NQO1, CBR1, NFE2L2 CDK2 863/4885CCNE2 567/4885CCNE1 989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.